GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Gross Margin %

Arovella Therapeutics (ASX:ALA) Gross Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Arovella Therapeutics's Gross Profit for the six months ended in Dec. 2023 was A$0.01 Mil. Arovella Therapeutics's Revenue for the six months ended in Dec. 2023 was A$0.01 Mil. Therefore, Arovella Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

Warning Sign:

Arovella Therapeutics Ltd gross margin has been in long-term decline. The average rate of decline per year is -13.8%.


The historical rank and industry rank for Arovella Therapeutics's Gross Margin % or its related term are showing as below:

ASX:ALA' s Gross Margin % Range Over the Past 10 Years
Min: 5.14   Med: 29.69   Max: 83.59
Current: 34.29


During the past 13 years, the highest Gross Margin % of Arovella Therapeutics was 83.59%. The lowest was 5.14%. And the median was 29.69%.

ASX:ALA's Gross Margin % is ranked worse than
74.56% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs ASX:ALA: 34.29

Arovella Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Arovella Therapeutics was -13.80% per year.


Arovella Therapeutics Gross Margin % Historical Data

The historical data trend for Arovella Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Gross Margin % Chart

Arovella Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.59 62.29 13.62 30.07 49.75

Arovella Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -365.22 63.37 52.37 11.54 -

Competitive Comparison of Arovella Therapeutics's Gross Margin %

For the Biotechnology subindustry, Arovella Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arovella Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Gross Margin % falls into.



Arovella Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Arovella Therapeutics's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=0.2 / 0.406
=(Revenue - Cost of Goods Sold) / Revenue
=(0.406 - 0.204) / 0.406
=49.75 %

Arovella Therapeutics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0.009
=(Revenue - Cost of Goods Sold) / Revenue
=(0.009 - 0) / 0.009
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Arovella Therapeutics  (ASX:ALA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Arovella Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Arovella Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arovella Therapeutics (ASX:ALA) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (ASX:ALA) Headlines

No Headlines